Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 4/2016

01-12-2016

Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers

Authors: Christoph Langenstein, Diana Schork, Klaus Badenhoop, Eva Herrmann

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2016

Login to get access

Abstract

Problem: Graves’ disease (GD) is an important and prevalent thyroid autoimmune disorder. Standard therapy for GD consists of antithyroid drugs (ATD) with treatment periods of around 12 months but relapse is frequent. Since predictors for relapse are difficult to identify the individual decision making for optimal treatment is often arbitrary. Methods: After reviewing the literature on this topic we summarize important factors involved in GD and with respect to their potential for relapse prediction from markers before and after treatment. This information was used to design a mathematical model integrating thyroid hormone parameters, thyroid size, antibody titers and a complex algorithm encompassing genetic predisposition, environmental exposures and current immune activity in order to arrive at a prognostic index for relapse risk after treatment. Conclusion: In the search for a tool to analyze and predict relapse in GD mathematical modeling is a promising approach. In analogy to mathematical modeling approaches in other diseases such as viral infections, we developed a differential equation model on the basis of published clinical trials in patients with GD. Although our model needs further evaluation to be applicable in a clinical context, it provides a perspective for an important contribution to a final statistical prediction model.
Footnotes
1
„Empirical models are based on direct observation, measurement and extensive data records. Mechanistic models are based on an understanding of the behavior of a system’s components. For example, you can observe the change of the tides over many years, and construct an empirical model that allows you to predict when tides will occur, with no understanding of how the earth, moon and sun interact. You can also create a mathematical, mechanistic model that uses the laws of physics to predict tides.” [78]
 
Literature
2.
go back to reference Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves’ disease. Exp Clin Endocrinol Diabetes. 1996;104(Suppl):98–100.CrossRefPubMed Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves’ disease. Exp Clin Endocrinol Diabetes. 1996;104(Suppl):98–100.CrossRefPubMed
3.
go back to reference Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817–9.CrossRefPubMedPubMedCentral Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817–9.CrossRefPubMedPubMedCentral
4.
go back to reference Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2014. doi:10.1111/cen.12688. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2014. doi:10.​1111/​cen.​12688.
6.
go back to reference Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.CrossRefPubMed Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.CrossRefPubMed
7.
go back to reference Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves’ disease relapse. Clin Endocrinol. 2005;63:657–62.CrossRef Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves’ disease relapse. Clin Endocrinol. 2005;63:657–62.CrossRef
9.
go back to reference Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–4.PubMed Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–4.PubMed
10.
go back to reference Ringold D. A, Nicoloff JT, Kesler M, Davis H, Hamilton a, Mack T: further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid. 2002;12:647–53.CrossRefPubMed Ringold D. A, Nicoloff JT, Kesler M, Davis H, Hamilton a, Mack T: further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid. 2002;12:647–53.CrossRefPubMed
11.
12.
go back to reference Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1–9.CrossRef Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1–9.CrossRef
13.
go back to reference Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid. 2002;12:849–53.CrossRefPubMed Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid. 2002;12:849–53.CrossRefPubMed
14.
go back to reference Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid. 2007;17:767–72.CrossRefPubMed Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid. 2007;17:767–72.CrossRefPubMed
15.
go back to reference Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immnunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254–7.PubMed Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immnunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254–7.PubMed
16.
go back to reference Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation. 2006;13:309–17.CrossRefPubMed Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation. 2006;13:309–17.CrossRefPubMed
17.
go back to reference Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485–98.CrossRefPubMedPubMedCentral Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485–98.CrossRefPubMedPubMedCentral
18.
go back to reference Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves’ disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329–35.CrossRefPubMed Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves’ disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329–35.CrossRefPubMed
19.
go back to reference Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613–7.CrossRefPubMed Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613–7.CrossRefPubMed
20.
go back to reference Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and helicobacter pylori: the correlation is present only in Graves’s disease. World J Gastroenterol. 2012;18:1093–7.CrossRefPubMedPubMedCentral Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and helicobacter pylori: the correlation is present only in Graves’s disease. World J Gastroenterol. 2012;18:1093–7.CrossRefPubMedPubMedCentral
21.
go back to reference Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–72.CrossRefPubMed Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–72.CrossRefPubMed
22.
go back to reference Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788–830.PubMed Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788–830.PubMed
23.
go back to reference Aleksić A, Aleksić Z, Stojanović M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves’ disease patients. Hell J Nucl Med. 2009;12:146–50.PubMed Aleksić A, Aleksić Z, Stojanović M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves’ disease patients. Hell J Nucl Med. 2009;12:146–50.PubMed
24.
go back to reference Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–80.CrossRefPubMed Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–80.CrossRefPubMed
25.
go back to reference Yu H, Farahani P. Thyroid stimulating hormone suppression post-therapy in patients with Graves’ disease: a systematic review of pathophysiology and clinical data. Clin Invest Med. 2015;38:E31–44.CrossRefPubMed Yu H, Farahani P. Thyroid stimulating hormone suppression post-therapy in patients with Graves’ disease: a systematic review of pathophysiology and clinical data. Clin Invest Med. 2015;38:E31–44.CrossRefPubMed
26.
go back to reference Neumann S, Place RF, Krieger CC, Gershengorn MC. Future prospects for the treatment of Graves’ hyperthyroidism and eye disease. Horm Metab Res. 2015;47:789–96.CrossRefPubMed Neumann S, Place RF, Krieger CC, Gershengorn MC. Future prospects for the treatment of Graves’ hyperthyroidism and eye disease. Horm Metab Res. 2015;47:789–96.CrossRefPubMed
27.
go back to reference Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Investig. 2014;37:1041–8.CrossRef Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Investig. 2014;37:1041–8.CrossRef
28.
go back to reference Wilson R, McKillop JH, Pearson C. Burnett a K, Thomson J a: differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol. 1988;73:312–5.PubMedPubMedCentral Wilson R, McKillop JH, Pearson C. Burnett a K, Thomson J a: differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol. 1988;73:312–5.PubMedPubMedCentral
29.
go back to reference Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001;7:451–60.CrossRefPubMed Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001;7:451–60.CrossRefPubMed
30.
go back to reference Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294:102–10.CrossRefPubMed Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294:102–10.CrossRefPubMed
31.
go back to reference Sopori M. 21 review: effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–7.CrossRefPubMed Sopori M. 21 review: effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–7.CrossRefPubMed
32.
go back to reference Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153–61.CrossRefPubMed Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153–61.CrossRefPubMed
33.
go back to reference Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419–27.CrossRefPubMed Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419–27.CrossRefPubMed
34.
35.
go back to reference Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn’s Colitis. 2014;8:717–25.CrossRef Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn’s Colitis. 2014;8:717–25.CrossRef
36.
go back to reference Guerra LN, Ríos De Molina MDC, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta. 2005;352:115–20.CrossRefPubMed Guerra LN, Ríos De Molina MDC, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta. 2005;352:115–20.CrossRefPubMed
37.
go back to reference Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78:155–64.CrossRef Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78:155–64.CrossRef
38.
go back to reference Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.CrossRefPubMed Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.CrossRefPubMed
39.
go back to reference Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;10:1–10. Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;10:1–10.
40.
go back to reference Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves’ disease outcome. Med. 2013;49:427–34. Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves’ disease outcome. Med. 2013;49:427–34.
41.
go back to reference Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996;81:2986–93.PubMed Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996;81:2986–93.PubMed
42.
go back to reference Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1:251–8.PubMed Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1:251–8.PubMed
43.
go back to reference Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol. 2007;67:607–12. Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol. 2007;67:607–12.
44.
go back to reference Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. 1989;120:689–701.PubMed Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. 1989;120:689–701.PubMed
45.
go back to reference Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid. 1998;8:119–24.CrossRefPubMed Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid. 1998;8:119–24.CrossRefPubMed
46.
go back to reference Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119–28.CrossRefPubMed Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119–28.CrossRefPubMed
47.
go back to reference Morshed SA, Davies TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47:727–34.CrossRefPubMedPubMedCentral Morshed SA, Davies TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47:727–34.CrossRefPubMedPubMedCentral
49.
go back to reference Davies TF, Ando T, Lin R-Y, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972–83.CrossRefPubMedPubMedCentral Davies TF, Ando T, Lin R-Y, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972–83.CrossRefPubMedPubMedCentral
50.
go back to reference Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al.: A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves ’ Disease 2014;564–567. Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al.: A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves ’ Disease 2014;564–567.
51.
go back to reference Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine. 2013;44:448–53.CrossRefPubMed Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine. 2013;44:448–53.CrossRefPubMed
52.
go back to reference Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:1. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:1.
53.
go back to reference Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease--prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50:127–32.CrossRef Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease--prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50:127–32.CrossRef
54.
go back to reference Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European multicentre trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol. 1998;49:451–7.CrossRef Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European multicentre trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol. 1998;49:451–7.CrossRef
55.
go back to reference Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European multicenter study group on antithyroid drug treatment. J Clin Endocrinol Metab. 1993;76:1516–21.PubMed Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European multicenter study group on antithyroid drug treatment. J Clin Endocrinol Metab. 1993;76:1516–21.PubMed
56.
go back to reference Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–61.CrossRefPubMed Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–61.CrossRefPubMed
57.
go back to reference Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease. Endocrine. 2015;48:254–63.CrossRefPubMed Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease. Endocrine. 2015;48:254–63.CrossRefPubMed
58.
go back to reference Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004;14:1047–55.CrossRefPubMed Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004;14:1047–55.CrossRefPubMed
59.
60.
go back to reference Vita R, Lapa D, Vita G, Trimarchi F, Benvenga S. A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab. 2009;5:55–61.CrossRefPubMed Vita R, Lapa D, Vita G, Trimarchi F, Benvenga S. A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab. 2009;5:55–61.CrossRefPubMed
61.
go back to reference Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985–8.CrossRefPubMed Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985–8.CrossRefPubMed
62.
go back to reference Smye SW, Clayton RH. Mathematical modelling for the new millenium: medicine by numbers. Med Eng Phys. 2002;24:565–74.CrossRefPubMed Smye SW, Clayton RH. Mathematical modelling for the new millenium: medicine by numbers. Med Eng Phys. 2002;24:565–74.CrossRefPubMed
64.
go back to reference Danziger, Elmergreen. Mathematical Theory of Periodic Relapsing Catatonia. Bull Math Biophys. 1954;16:15–21.CrossRef Danziger, Elmergreen. Mathematical Theory of Periodic Relapsing Catatonia. Bull Math Biophys. 1954;16:15–21.CrossRef
65.
go back to reference Danziger, Elmergreen. The thyroid-pituitary homeostatic mechanism. Bull Math Biophys. 1956;18:1–13.CrossRef Danziger, Elmergreen. The thyroid-pituitary homeostatic mechanism. Bull Math Biophys. 1956;18:1–13.CrossRef
66.
go back to reference Rashevsky N. Mathematical theory of biological periodicities: formulation of the n-body case. Bull Math Biophys. 1968;30:735–49.CrossRefPubMed Rashevsky N. Mathematical theory of biological periodicities: formulation of the n-body case. Bull Math Biophys. 1968;30:735–49.CrossRefPubMed
67.
go back to reference Norwich K, Raymond R. Homeostatic control of the thyroxin concentration expressed by a set of linear differential equations. Bull Math Biophys. 1965;27:133–44.CrossRefPubMed Norwich K, Raymond R. Homeostatic control of the thyroxin concentration expressed by a set of linear differential equations. Bull Math Biophys. 1965;27:133–44.CrossRefPubMed
68.
go back to reference DiStefano J, Stear E. Neuroendocrine control of thyroid secretion in living systems: a feedback control system model. Bull Math Biophys. 1968;30:8–26. DiStefano J, Stear E. Neuroendocrine control of thyroid secretion in living systems: a feedback control system model. Bull Math Biophys. 1968;30:8–26.
69.
go back to reference Hatakeyama T, Yagi H. Computer simulation for hormones related to primary Thyropathy. Biol Cybern. 1985;52:259–66.CrossRefPubMed Hatakeyama T, Yagi H. Computer simulation for hormones related to primary Thyropathy. Biol Cybern. 1985;52:259–66.CrossRefPubMed
70.
go back to reference Liu Y, Liu B, Xie J, Liu YX. A new mathematical model of hypothalamo-pituitary-thyroid axis. Math Comput Model. 1994;19:81–90.CrossRef Liu Y, Liu B, Xie J, Liu YX. A new mathematical model of hypothalamo-pituitary-thyroid axis. Math Comput Model. 1994;19:81–90.CrossRef
71.
go back to reference Degon M, Chipkin SR, Hollot CV, Zoeller RT, Chait Y. A computational model of the human thyroid. Math Biosci. 2008;212:22–53.CrossRefPubMed Degon M, Chipkin SR, Hollot CV, Zoeller RT, Chait Y. A computational model of the human thyroid. Math Biosci. 2008;212:22–53.CrossRefPubMed
72.
go back to reference Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. 2010;162:1123–9.CrossRefPubMed Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. 2010;162:1123–9.CrossRefPubMed
73.
go back to reference Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto’s) thyroiditis. Math Med Biol. 2014;31:226–58.CrossRefPubMed Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto’s) thyroiditis. Math Med Biol. 2014;31:226–58.CrossRefPubMed
74.
go back to reference Silver N, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Brain. 1997;120:1149–61.CrossRefPubMed Silver N, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Brain. 1997;120:1149–61.CrossRefPubMed
75.
go back to reference Velez de Mendizabal N, Hutmacher MM, Troconiz IF, Goni J, Villoslada P, Bagnato F, et al. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. PLoS One. 2013;8. doi:10.1371/journal.pone.0073361. Velez de Mendizabal N, Hutmacher MM, Troconiz IF, Goni J, Villoslada P, Bagnato F, et al. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. PLoS One. 2013;8. doi:10.​1371/​journal.​pone.​0073361.
76.
go back to reference Goede SL. Leow MK-SS, Smit JWA, Klein HH, Dietrich JW: hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol. 2014;76:1270–87.CrossRefPubMed Goede SL. Leow MK-SS, Smit JWA, Klein HH, Dietrich JW: hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol. 2014;76:1270–87.CrossRefPubMed
77.
go back to reference Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol. 2013;78:768–76.CrossRef Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol. 2013;78:768–76.CrossRef
Metadata
Title
Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers
Authors
Christoph Langenstein
Diana Schork
Klaus Badenhoop
Eva Herrmann
Publication date
01-12-2016
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2016
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9386-8

Other articles of this Issue 4/2016

Reviews in Endocrine and Metabolic Disorders 4/2016 Go to the issue